Dr Julie Simmonds

Research – Healthcare

id="main" class="site-main" role="main"> }

Dr Julie Simmonds

Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 18 years’ experience in Life Sciences research, covering both UK and continental European companies across a wide range of Healthcare subsectors. These include biotechnology, medical devices, diagnostics and healthcare services across both large and small-cap companies.

Prior to Canaccord Genuity Julie was a member of the No.1 Extel‑rated healthcare team at Piper Jaffray. Julie started her City career at Beeson Gregory, where she became Head of Lifesciences research.

Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also panel member for NIHR i4i (invention for innovation), assessing early stage medical technologies.


Freddy Crossley

Freddy has 15 years experience, joining Panmure Gordon in 2012. He began his career as a graduate at Charles Stanley stockbrokers, and subsequently worked at Seymour Pierce where he acted for many clients particularly in the Healthcare and Technology sector.

Freddy has led numerous M&A and equity market transactions on both AIM and the Official List including Class 1 transactions, secondary fundraisings and IPOs, and managed the recent IPOs of Horizon Discovery, Midatech and Focusrite.

Freddy holds a BSc Hons in Human Physiology from Bristol University.

Ian Gibson

Ian joined Panmure Gordon in 2013 to head its marketmaking desk having previously worked at JP Morgan Cazenove running its UK Mid Cap equities arm.

He began his City career in 1987 at Hoare Govett working on a number of desks before the firm was taken over by ABN Amro.

He moved to Commerzbank Securities in 2000 to help set up and run its Pan Euro equities business before joining Cazenove in 2005.

He ran mid cap trading at Cazenove before the company merged with JP Morgan in 2010 – bringing a number of IPO’s to market and helping corporate clients on placings and sensitive stake building strategies.

Dr Mike Mitchell

Mike joined the Research team at Panmure Gordon in November 2012. Before joining Panmure he spent three years at Seymour Pierce, where he helped to build the healthcare sector franchise into one of the leading small cap teams in London.  Prior to this, he worked at Oriel Securities and Teather & Greenwood, having commenced his City career with Evolution Capital in 2001.

A multiple No.1-ranked Thomson Reuters Starmine Award winner (2005, 2010, 2011), Mike’s technical background is underpinned by his career as a research scientist including postdoctoral appointments in the US (Bloomington) and UK (Imperial College), having gained his PhD in Chemistry in 1997 (Leeds).